[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Argenx Se ADR (ARGX)

Argenx Se ADR (ARGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,368,396
  • Shares Outstanding, K 61,883
  • Annual Sales, $ 4,248 M
  • Annual Income, $ 1,292 M
  • EBIT $ 915 M
  • EBITDA $ 1,082 M
  • 60-Month Beta 0.46
  • Price/Sales 11.31
  • Price/Cash Flow 36.39
  • Price/Book 6.56

Options Overview Details

View History
  • Implied Volatility 34.79% (-0.19%)
  • Historical Volatility 31.03%
  • IV Percentile 42%
  • IV Rank 42.76%
  • IV High 46.46% on 10/28/25
  • IV Low 26.07% on 08/06/25
  • Expected Move (DTE 29) 53.38 (6.69%)
  • Put/Call Vol Ratio 0.67
  • Today's Volume 10
  • Volume Avg (30-Day) 221
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 6,549
  • Open Int (30-Day) 6,709
  • Expected Range 744.82 to 851.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $6.07
  • Number of Estimates 10
  • High Estimate $7.37
  • Low Estimate $4.35
  • Prior Year $3.74
  • Growth Rate Est. (year over year) +62.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
754.84 +5.96%
on 04/29/26
840.67 -4.86%
on 05/07/26
-34.63 (-4.15%)
since 04/20/26
3-Month
661.85 +20.85%
on 03/20/26
852.28 -6.16%
on 04/17/26
-44.59 (-5.28%)
since 02/20/26
52-Week
510.05 +56.81%
on 06/30/25
934.62 -14.42%
on 12/03/25
+221.51 (+38.30%)
since 05/20/25

Most Recent Stories

More News
The Biology Came First.

Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth...

CGEM : 14.17 (-0.07%)
IDXX : 552.73 (+1.14%)
IPA : 2.07 (+7.25%)
ARGX : 802.54 (+0.60%)
XNCR : 11.16 (+7.20%)
HYFT : 1.4900 (+18.25%)
2 Ways to Play the Big Pharma Patent Cliff

With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.

NVO : 45.04 (+1.72%)
IBB : 167.04 (+1.74%)
ARGX : 802.54 (+0.60%)
PFE : 25.82 (+0.62%)
XBI : 130.95 (+3.28%)
argenex Q1 Earnings Call Highlights

argenx (NASDAQ:ARGX) reported first-quarter 2026 results highlighting continued commercial growth for VYVGART and progress across multiple late-stage pipeline programs, while newly appointed CEO Karen...

ARGX : 802.54 (+0.60%)
Argenx Reports Tomorrow With Analysts Apparently Forgetting What Biotech Valuations Mean

Barchart Research What to Expect from ARGX Earnings ARGX Generated May 6, 2026 Current Price $807.55 EPS Estimate $$5.16 Consensus Rating Strong Buy Average Move 4.81% Argenx Reports Tomorrow With Analysts...

ARGX : 802.54 (+0.60%)
argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada

TORONTO , Nov. 5, 2025 /CNW/ - argenx SE (EURONEXT: ARGX) (Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...

ARGX : 802.54 (+0.60%)
Analysts Offer Insights on Healthcare Companies: Microbot Medical (MBOT), Argenx Se (ARGX) and AnaptysBio (ANAB)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Microbot Medical (MBOT – Research Report), Argenx Se (ARGX – Research Report) and AnaptysBio (ANAB –...

ANAB : 60.54 (+1.29%)
ARGX : 802.54 (+0.60%)
MBOT : 1.7450 (+0.87%)
Argenx SE Showcases Immunology Innovations at 2025 AANEM Meeting

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An update...

ARGX : 802.54 (+0.60%)
TD Cowen Remains a Buy on Argenx Se (ARGX)

In a report released today, Yaron Werber from TD Cowen reiterated a Buy rating on Argenx Se, with a price target of $800.00. The company’s shares closed yesterday at $812.95.Elevate Your Investing Strategy:...

ARGX : 802.54 (+0.60%)
Argenx Se (ARGX) Gets a Buy from Evercore ISI

Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Argenx Se yesterday and set a price target of $775.00. The company’s shares closed yesterday at $799.56.Elevate Your Investing Strategy:...

ARGX : 802.54 (+0.60%)
RBC Capital Remains a Buy on Argenx Se (ARGX)

In a report released on October 8, Luca Issi from RBC Capital maintained a Buy rating on Argenx Se. The company’s shares closed yesterday at $804.90.Elevate Your Investing Strategy: Take advantage of...

ARGX : 802.54 (+0.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands.

See More

Key Turning Points

3rd Resistance Point 830.50
2nd Resistance Point 815.10
1st Resistance Point 806.43
Last Price 802.54
1st Support Level 782.36
2nd Support Level 766.96
3rd Support Level 758.29

See More

52-Week High 934.62
Last Price 802.54
Fibonacci 61.8% 772.44
Fibonacci 50% 722.34
Fibonacci 38.2% 672.24
52-Week Low 510.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.